RenovoRx (RNXT) Research & Development (2020 - 2026)

RenovoRx has disclosed Research & Development across 7 years of filings, most recently posting $1.2 million for Q2 2026.

• In Q2 2026, Research & Development fell 15.85% year-over-year to $1.2 million; the TTM figure through Jun 2026 stood at $5.6 million (down 10.8% YoY), while the FY2025 annual figure was $6.3 million, up 4.05% from the prior year.
• Research & Development came in at $1.2 million for Q2 2026 at RenovoRx, down from $1.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $1.9 million in Q2 2023 to a low of $775000.0 in Q4 2023.
• Average Research & Development over 5 years is $1.4 million, with a median of $1.4 million recorded in 2022.
• The largest YoY upside for Research & Development was 159.33% in 2022 against a maximum downside of 29.52% in 2022.
• Over 5 years, Research & Development stood at $776000.0 in 2022, then slipped by 0.13% to $775000.0 in 2023, then surged by 103.35% to $1.6 million in 2024, then dropped by 4.76% to $1.5 million in 2025, then dropped by 20.05% to $1.2 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $1.2 million in Q2 2026, $1.2 million in Q1 2026, and $1.5 million in Q4 2025.